MedPath

Famotidine

Generic Name
Famotidine
Brand Names
Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
Drug Type
Small Molecule
Chemical Formula
C8H15N7O2S3
CAS Number
76824-35-6
Unique Ingredient Identifier
5QZO15J2Z8
Background

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.

It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.

The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.

Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.

Associated Conditions
Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

Phase 1
Completed
Conditions
Fibrosis
Interventions
First Posted Date
2017-05-05
Last Posted Date
2018-01-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
33
Registration Number
NCT03142165
Locations
🇺🇸

Wcct Global, Llc, Cypress, California, United States

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

Phase 2
Completed
Conditions
HPV-Related Squamous Cell Carcinoma
HNSCC
Interventions
First Posted Date
2017-04-11
Last Posted Date
2025-05-06
Lead Sponsor
University of Chicago
Target Recruit Count
72
Registration Number
NCT03107182
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis

Phase 1
Completed
Conditions
Psoriasis
Interventions
Drug: Placebo
Drug: Interferon alpha-2a recombinant
First Posted Date
2016-05-05
Last Posted Date
2017-08-03
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
357
Registration Number
NCT02763969
Locations
🇦🇺

Local Institution, Melbourne, Australia

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2016-02-18
Last Posted Date
2017-11-24
Lead Sponsor
Tobira Therapeutics, Inc.
Target Recruit Count
48
Registration Number
NCT02684799
Locations
🇺🇸

SeaView Research, Inc., Miami, Florida, United States

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

First Posted Date
2015-09-22
Last Posted Date
2015-09-22
Lead Sponsor
Canadian Network for Observational Drug Effect Studies, CNODES
Target Recruit Count
4238504
Registration Number
NCT02555852
Locations
🇨🇦

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Interferon alpha-2a recombinant
Other: Placebo
First Posted Date
2015-08-27
Last Posted Date
2016-12-28
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
140
Registration Number
NCT02534636
Locations
🇦🇺

Local Institution, Melbourne, Victoria, Australia

Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)

Not Applicable
Completed
Conditions
Post-Operative Nausea and Vomiting
Breast Cancer
Interventions
Procedure: Electrical Stimulation
Behavioral: Questionnaire
First Posted Date
2015-06-16
Last Posted Date
2024-12-16
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
187
Registration Number
NCT02473042
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Anesthetics in Rhytidoplasty - A Comparison Study

First Posted Date
2015-04-07
Last Posted Date
2015-04-07
Lead Sponsor
Mercy Facial Plastic Surgery Center
Target Recruit Count
30
Registration Number
NCT02410460
Locations
🇺🇸

Mercy Facial Plastic Surgery Center, Springfield, Missouri, United States

Histamine Glutamate Antagonism in Stroke

Phase 2
Completed
Conditions
Acute Cerebrovascular Accident
Cerebral Edema
Interventions
First Posted Date
2014-05-20
Last Posted Date
2015-12-15
Lead Sponsor
University of Florida
Target Recruit Count
3
Registration Number
NCT02142712
Locations
🇺🇸

Shands Hospital at University of Florida, Gainesville, Florida, United States

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

First Posted Date
2014-03-27
Last Posted Date
2014-06-19
Lead Sponsor
Pfizer
Target Recruit Count
27
Registration Number
NCT02097329
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath